SCA
BIO icon

Southpoint Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Southpoint Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$34.6M – 48
2024
Q1 		$34.6M Buy
+100,000
New +$32.9M 0.68% 42

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Southpoint Capital Advisors's BIO Position: Q2 2024 in Review

Southpoint Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 100,000 shares — an estimated $34.6M sold.

Southpoint Capital Advisors first reported a position in BIO in Q1 2024 and held it in 1 quarter. The position peaked at $34.6M in Q1 2024. 439 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

  • Southpoint Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
  • Southpoint Capital Advisors sold 100,000 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $34.6M.
  • Southpoint Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2024 and held it in 1 quarter.
  • Southpoint Capital Advisors's Bio-Rad Laboratories Class A position peaked at $34.6M in Q1 2024.
  • 439 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Southpoint Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.